Eisai, Biogen Launch Rolling BLA for Subcutaneous Alzheimer’s Therapy Leqembi 5/15/2024

Winners and Losers in Biopharma’s Q1 2024 Earnings Season 5/15/2024

Sands Capital Launches $555M Life Sciences Fund Focusing on Private Companies 5/15/2024

As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters 5/15/2024

FDA Delays Review by Three Months for Ascendis’ Hypoparathyroidism Therapy 5/15/2024

The Many Ways Biopharma Can Use Artificial Intelligence, Including Generative AI 5/15/2024

Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap 5/15/2024

Deaths from cancer or infections can occur when available treatments are ineffective. Once turned on, pregnane X receptor (PXR) activates the expression of genes encoding enzymes that metabolize external chemicals, including drugs. This causes a significant drop in the effectiveness of chemotherapy, antivirals and other pharmaceuticals. Blocking the PXR activity is notoriously difficult, as many drugs that bind the protein, whether intentionally or unintentionally, activate it. Scientists at St. Jude Children’s Research Hospital have leveraged chemical and structural studies in the design of PXR inhibitors to better understand this process.

Bayer Cuts 1,500 Jobs and Lowers 2024 Earnings Guidance as Q1 Sales Dip 5/14/2024

Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years in Two Studies 5/14/2024

Cytokinetics’ Phase III Data Sets Up Cardiomyopathy Challenge to BMS 5/14/2024

AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Next-Gen Psychedelics for Psychiatric Disorders 5/14/2024

Researchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an infected individual, which suggests that the therapy would also reduce the spread of the virus.

"Herpes is very sneaky. It hides out among nerve cells and then reawakens and causes painful skin blisters," said Keith Jerome, MD, PhD, professor in the Vaccine and Infectious Disease Division at Fred Hutch.

Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France 5/13/2024

Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts 5/13/2024

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy 5/13/2024

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs 5/13/2024

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy? 5/13/2024

Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market 5/13/2024

FDA Action Alert: Dynavax, Ascendis and BMS 5/13/2024